This Study Tests the Effect of Risankizumab on the Metabolism in the Liver of Five Additional Drugs to Study Possible Drug Interactions in Patients With Psoriasis With or Without Psoriatic Arthritis

Phase 1 Completed 21 enrolled AbbVie Boehringer Ingelheim · collab

NaSingle-groupOpen-labelTreatment

To assess the influence of risankizumab on kinetics of cytochrome P450 (CYP) probe drugs as a means of predicting drug-drug interactions.

Evaluation	Drug	Modality	Dose	Route
Subject	Caffeine	Small molecule	100 mg	Oral
Subject	Metoprolol	Other / unclassified	50 mg	Oral
Subject	Midazolam	Small molecule	2 mg	Oral
Subject	Omeprazole	Other / unclassified	20 mg	Oral
Subject	Risankizumab	Monoclonal antibody	150 mg	Subcutaneous
Subject	Warfarin	Small molecule	10 mg	Oral